All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Johnson & Johnson, Syndax, Thermo Fisher Scientific, Kura Oncology, AbbVie, and has been supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group.
Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View AML content recommended for you
CLTR0310-301 phase III post hoc analysis: CPX‑351 vs 7 + 3 in genetic subgroups of AML
A post hoc analysis of the randomized, multicenter, phase III CLTR0310‑301 study (NCT01696084) evaluated survival benefit with CPX‑351 vs cytarabine + anthracycline (7 + 3) chemotherapy in genetically defined subgroups of older patients (aged 60–75 years) with untreated, high-risk acute myeloid leukemia (AML). DNA sequencing reclassified patients, based on mutational status, into TP53-mutated (TP53m) AML (n = 62), DDX41-mutated (DDX41m) AML (n = 10), myelodysplasia-related AML (AML‑MR; n = 88), and other-AML (n = 24) subgroups. Overall survival (OS) and response rates were assessed among genetically defined AML subgroups. Results were published in Blood Advances by Shimony et al.
Key data: Complete remission (CR) / CR with incomplete hematologic response (CRi) rates varied across molecular subgroups at 35% in TP53m AML, 100% in DDX41m AML, 38% in AML‑MR, and 63% in other-AML (p < 0.001), but did not significantly differ between treatment arms within each subgroup. Median OS in patients with AML‑MR treated with CPX‑351 was 9.7 months (95% confidence interval [CI], 6.2–13.7) vs 6.8 months in those treated with 7 + 3 (95% CI, 3.6–9.6; p = 0.037). No survival differences were observed between treatment arms in the TP53m AML (p = 0.70), other-AML (p = 0.77), or DDX41m AML (p = 0.11) subgroups. Among patients with AML‑MR who received allogeneic hematopoietic stem cell transplantation (allo-HSCT), induction with CPX‑351 was associated with longer survival vs 7 + 3 (2-year OS, 76% vs 27%).
Key learning: Results indicate that CPX‑351 may be an effective therapeutic option for older transplant-eligible patients with AML‑MR, while lack of efficacy in the TP53m AML subgroup limits its role in patients with TP53m AML. Further studies evaluating efficacy across molecular subgroups are needed to reach definitive conclusions on survival outcomes with CPX‑351 in different AML subtypes.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
